References
- Miller H. I., Wardell W. M. Therapeutic Drugs and Biologies. In Advancing Medical Innovation: Health, Safety and the Role of Government In the 21st Century. The Progress and Freedom Foundation. Washington, DC 1996
- DiMasi J., et al. Estimate is in pretax 1990. Washington, DC February, 1993, The Boston Consulting Group analysis based on dollars as quoted by the Office of Technology Assessment in Pharmaceutical R&D: Costs, Risks, and Rewards 1991.
- Anonymous. Adverse Experience Reporting Requirements for Human Drug and Licensed Biological Product. Federal Register 1995; 59
- Meinert C. L. Controlled Clinical Trials, in press
- Henderson D. R. FDA Censorship Can Be Hazardous to Your Health, Policy Brief 158. Center for the Study of American Business, St. Louis, MO September, 1995
- Anonymous. A National Survey of Oncologists Regarding the Food and Drug Administration. Competitive Enterprise Institute, Washington, DC 1995
- Anonymous. A National Survey of Cardiologists Regarding the Food and Drug Administration. Competitive Enterprise Institute, Washington, DC July, 1996
- Anonymous. The Impact of the House FDA Reform Proposals. Food and Drug Administration. 1996
- Giaquinto A. R. Letter to House Commerce Committee from Schering. Plough Research Institute. May 14, 1996